Harmony Biosciences Holdings, Inc.
HealthcareNASDAQ:HRMY · NASDAQ Global Market
-$0.74 today
Vol 0.69M · Avg 0.81M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.2%
avg 169.5%
ROIC
13.9%
avg -14.9%
ROA
12.5%
avg -14.7%
Analysis
ROE is currently the strongest return metric at 18.2% versus its period average of 169.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey Dayno | President, Chief Executive Officer & Director | $1.32M | — | 69 | $39,000.00 | 0.07% |
Adam Zaeske | Executive Vice President & Chief Commercial Officer | $946,228.00 | — | 53 | $7,500.00 | 0.01% |
Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer | $919,062.00 | — | 55 | $32,997.00 | 0.06% |
Andrew Serafin | Executive Vice President & Chief Strategy Officer | $681,398.00 | — | 51 | $1,474.00 | <0.01% |
Jeffrey S. Aronin | Founder & Non-Executive Chairman | $77,500.00 | — | 58 | $39,000.00 | 0.07% |
Peter Anastasiou | Chief Operating Officer | $58,250.00 | — | 56 | $212,241.00 | 0.37% |
Tricia Glover | Chief Compliance Officer | — | — | — | — | — |
Brennan Doyle | Vice President & Head of Investor Relations | — | — | — | — | — |
Christian Ulrich | Executive VP, General Counsel & Corporate Secretary | — | — | — | — | — |
Glenn Reicin | Chief Financial Officer | — | — | 61 | $164,309.00 | 0.28% |
Audrey Murphy | Chief Human Resources Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$2.83M
Net Sentiment
$2.83M
Net selling
Most Active
Kapadia Sandip
5 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $2.83M over the last 12 months. That adds up to net selling of $2.83M. Kapadia Sandip was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +7.8% (8yr)4 analysts |
| Revenue | N/A | N/A | +318.0% | +14.1% (8yr)5 analysts |
| Net Income | N/A | N/A | N/A | +7.2% (8yr)5 analysts |
| EBIT | N/A | N/A | N/A | +16.7% (8yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at +318.0% over three years. Forward estimates point to EBIT at +16.7% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Biohaven Ltd.
NYSE:BHVN
$1.19B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages HRMY?
Harmony Biosciences Holdings, Inc. (HRMY) lists 11 active executives. The top listed executive is Tricia Glover, Chief Compliance Officer.
Are HRMY insiders buying or selling?
Recent insider activity shows net selling of $209.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.